NASDAQ:LGND

Ligand Pharmaceuticals Competitors

$153.44
-2.20 (-1.41 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$152.50
Now: $153.44
$156.06
50-Day Range
$139.34
MA: $152.03
$165.98
52-Week Range
$78.26
Now: $153.44
$219.75
Volume116,541 shs
Average Volume576,965 shs
Market Capitalization$2.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46

Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying LGND stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Ligand Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Risk & Volatility

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Amgen and Ligand Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0101402.58
Ligand Pharmaceuticals01502.83

Amgen presently has a consensus target price of $259.4091, indicating a potential upside of 4.20%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Amgen and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Ligand Pharmaceuticals-11.23%5.90%3.22%

Earnings and Valuation

This table compares Amgen and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.14$7.84 billion$14.8216.80
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72

Amgen has higher revenue and earnings than Ligand Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Gilead Sciences and Ligand Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
Ligand Pharmaceuticals01502.83

Gilead Sciences presently has a consensus target price of $97.2308, indicating a potential upside of 49.33%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Gilead Sciences and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Ligand Pharmaceuticals-11.23%5.90%3.22%

Valuation and Earnings

This table compares Gilead Sciences and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Ligand Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72

Vertex Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vertex Pharmaceuticals and Ligand Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Ligand Pharmaceuticals01502.83

Vertex Pharmaceuticals presently has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Ligand Pharmaceuticals' higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Ligand Pharmaceuticals-11.23%5.90%3.22%

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Ligand Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13

Regeneron Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01502.83
Regeneron Pharmaceuticals051412.80

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Regeneron Pharmaceuticals has a consensus price target of $637.2083, indicating a potential upside of 34.10%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Ligand Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72
Biogen$14.38 billion2.84$5.89 billion$33.577.99

Biogen has higher revenue and earnings than Ligand Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01502.83
Biogen5141202.23

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Biogen has a consensus price target of $303.5517, indicating a potential upside of 13.19%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Ligand Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Biogen35.63%51.00%23.54%

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Biogen beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million21.19$629.30 million$2.1172.72
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91

Alexion Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01502.83
Alexion Pharmaceuticals017512.30

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 0.74%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Ligand Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95-0.8%$143.35 billion$23.36 billion20.08Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11-0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35-1.4%$55.46 billion$4.16 billion26.94Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17-0.3%$50.91 billion$7.86 billion17.37News Coverage
Biogen logo
BIIB
Biogen
1.9$268.17-0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01-0.3%$34.08 billion$4.99 billion36.22
Seagen logo
SGEN
Seagen
1.7$142.85-1.1%$25.90 billion$916.71 million56.24Insider Selling
News Coverage
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.54-2.4%$21.23 billion$876.29 million-56.81Gap Down
Incyte logo
INCY
Incyte
1.9$79.96-1.1%$17.58 billion$2.16 billion-50.93News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23-3.1%$16.22 billion$219.75 million-17.65News Coverage
Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Novavax logo
NVAX
Novavax
1.6$179.74-1.9%$13.28 billion$18.66 million-34.43Insider Selling
Gap Up
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$23.12-1.0%$7.21 billion$967.78 million48.17
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16-1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Codexis logo
CDXS
Codexis
1.1$24.00-2.6%$1.55 billion$68.46 million-68.57Insider Selling
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71-1.4%$820.43 million$3.57 million-9.29Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.